目的 对比地屈孕酮与黄体酮分别联合HCG治疗原因不明复发性流产（URSA）患者的临床疗效差异。方法 将我院接 诊的125例URSA患者随机分成两组：观察组63例(HCG+地屈孕酮治疗)，对照组62例(HCG+黄体酮治疗)，比较两组孕 激素（P）、HCG检测指标及妊娠结局与副反应差异。结果 孕期6-8周内，两组P指标差异不明显（P>0.05），观察 组HCG指标明显高于对照组（P<0.05）；孕10-12周内，观察组P、HCG指标均明显高于对照组（P<0.05）；两组足月 分娩、流产、副反应各项数据组间对比差异显著，且观察组各项更理想（P<0.05）。结论 在联合HCG下，地屈孕酮 较黄体酮治疗URSA的临床疗效更佳，无明显副反应，值得推广。

Objective To compare the clinical therapeutic efficacy of Dydrogesterone and Progesterone combined with HCG respectively in the treatment of Unexplained recurrent spontaneous abortion(URSA). Methods A total of 125 patients diagnosed URSA in Zhuhai Maternity and Child Health Hospital were randomly divided into two groups, with 63 cases (Dydrogesterone Group) treated by dydrogesterone combined with HCG and 62 cases (Progesterone Group) treated by Progesterone combined with HCG. The serum P, HCG and the pregnancy outcomes and adverse reactions of patients in two groups were compared respectively. Results Within 6-8 gestational weeks, the serum P in two groups showed no significant difference(P>0.05), but the serum HCG of the Dydrogesterone Group was higher than that of the Progesterone Group (P<0.05). During 10-12 gestational weeks, the serum P and HCG of Dydrogesterone Group were all significantly higher than Progesterone Group (P<0.05). The abortion rate, the term birth rate, and adverse reaction rate in two groups were obviously different (P<0.05). The abortion rate and adverse reaction rate of the Dydrogesterone Group were lower, but the term birth rate was higher. Conclusion In combination with HCG, the therapy on URSA by dydrogesterone has the better clinical effects than by progesterone, and has fewer adverse reactions as well,thus worth spreading.